K. Swenerton

G. Pond, A. Oza, K. Swenerton, 2005, International journal of gynecological cancer : official journal of the International Gynecological Cancer Society.

Long-term follow-up confirms a survival advantage of the paclitaxel–cisplatin regimen over the cyclophosphamide–cisplatin combination in advanced ovarian cancer

M. Piccart, K. Swenerton, I. Vergote, 2003, International Journal of Gynecologic Cancer.

Intergroup collaboration in ovarian cancer: a giant step forward

M. Piccart, M. Parmar, E. Eisenhauer, 1999 .

A phase I study of bi-weekly paclitaxel/cisplatin as initial therapy for advanced ovarian cancer. A study of the National Cancer Institute of Canada Clinical Trials Group.

E. Eisenhauer, K. Swenerton, G. Batist, 1996, Annals of oncology : official journal of the European Society for Medical Oncology.

Genome-wide association study of subtype-specific epithelial ovarian cancer risk alleles using pooled DNA

Lara E Sucheston-Campbell, Lara E. Sucheston-Campbell, A. Whittemore, 2013, Human Genetics.

Functional Proteomic Analysis of Advanced Serous Ovarian Cancer Using Reverse Phase Protein Array: TGF-β Pathway Signaling Indicates Response to Primary Chemotherapy

Fan Zhang, Yiling Lu, Gordon B Mills, 2010, Clinical Cancer Research.

Cisplatin-cyclophosphamide versus carboplatin-cyclophosphamide in advanced ovarian cancer: a randomized phase III study of the National Cancer Institute of Canada Clinical Trials Group.

K. Swenerton, G. Stuart, M. Roy, 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The Significance of Combination Chemotherapy in Epithelial Ovarian Cancer

K. Swenerton, M. Carey, J. Kwon, 2014, International Journal of Gynecologic Cancer.

Neoadjuvant chemotherapy followed by vaginal radical trachelectomy in bulky stage IB1 cervical cancer: case report.

K. Swenerton, S. Lau, M. Plante, 2006, Gynecologic oncology.

Carboplatin plus paclitaxel for advanced or recurrent uterine malignant mixed mullerian tumors. The British Columbia Cancer Agency experience.

A. Tinker, N. Le, K. Swenerton, 2008, Gynecologic oncology.

Carboplatin and paclitaxel for advanced and recurrent cervical carcinoma: the British Columbia Cancer Agency experience.

A. Tinker, K. Swenerton, P. Hoskins, 2005, Gynecologic oncology.

Carboplatin in the treatment of carcinoma of the ovary: the National Cancer Institute of Canada experience. Ovarian Cancer Subcommittee.

K. Swenerton, J. Pater, Joseph L. Pater, 1992, Seminars in oncology.

Modeling toxicity and response in carboplatin-based combination chemotherapy.

K. Swenerton, J. Burroughs, D. Jodrell, 1994, Seminars in oncology.

Combined methotrexate-dactinomycin: an effective therapy for low-risk gestational trophoblastic neoplasia.

K. Swenerton, H. Steed, P. Hoskins, 2012, Gynecologic oncology.

Cisplatin/etoposide chemotherapy for recurrent or primarily advanced cervical carcinoma.

K. Swenerton, P. Hoskins, J. Pike, 1997, Gynecologic Oncology.

Carboplatin plus paclitaxel for advanced or recurrent uterine malignant mixed mullerian tumors. The British Columbia Cancer Agency experience.

A. Tinker, N. Le, K. Swenerton, 2008, Gynecologic oncology.

Toxicity of Abdominopelvic Radiation in Advanced Ovarian Carcinoma Patients After Cisplatin/Cyclophosphamide Therapy and Second-Look Laparotomy

K. Swenerton, W. Shelley, M. Roy, 1988, Obstetrics and gynecology.

Paclitaxel and carboplatin, alone or with irradiation, in advanced or recurrent endometrial cancer: a phase II study.

K. Swenerton, P. Hoskins, P. Lim, 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

P a c litaxel a nd C arboplatin, A lone o r W ith I rradiation, i n Advanced o r R ecurrent E ndometrial C ancer: A P hase I I S tudy

K. Swenerton, P. Hoskins, P. Lim, 2001 .

Endometrial adenocarcinoma presenting as an isolated calcaneal metastasis. A rare entity with good prognosis

K. Swenerton, F. Wong, John K. Cooper, 1994, Cancer.

Intergroup collaboration in ovarian cancer: a giant step forward.

M. Piccart, M. Parmar, E. Eisenhauer, 1999, Annals of Oncology.

Re: Gynecologic surgeries and risk of ovarian cancer in women with BRCA1 and BRCA2 Ashkenazi founder mutations: an Israeli population-based case-control study.

W. Foulkes, K. Swenerton, S. Narod, 2003, Journal of the National Cancer Institute.

Potential underdosing of carboplatin in gynecological malignancies.

K. Swenerton, M. D. de Lemos, L. Hamata, 2006, Gynecologic oncology.

Significance of sialic acid and carcinoembryonic antigen as monitors of tumor burden among patients with carcinoma of the ovary.

K. Swenerton, F. A. Salinas, H. Silver, 1981, Surgery, gynecology & obstetrics.

Survival Benefit of Adjuvant Radiotherapy: An Analysis of Low-Stage Invasive Ovarian Mucinous Carcinomas

A. Tinker, N. Le, K. Swenerton, 2017, International Journal of Gynecologic Cancer.

Small-cell carcinoma of the cervix: fourteen years of experience at a single institution using a combined-modality regimen of involved-field irradiation and platinum-based combination chemotherapy.

K. Swenerton, C. Aquino-Parsons, P. Hoskins, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Stage II to IV Low-grade Serous Carcinoma of the Ovary Is Associated With a Poor Prognosis: A Clinicopathologic Study of 32 Patients From a Population-based Tumor Registry

S. Kalloger, K. Swenerton, C. Gilks, 2013, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.

The Impact of Geographic Variations in Treatment on Outcomes in Ovarian Cancer

K. Swenerton, M. Carey, J. Kwon, 2012, International Journal of Gynecologic Cancer.

Tumor cell type can be reproducibly diagnosed and is of independent prognostic significance in patients with maximally debulked ovarian carcinoma.

Nhu Le, C Blake Gilks, N. Le, 2008, Human pathology.

Gliomatosis peritonei with malignant transformation.

K. Swenerton, P. Clement, F. Dadmanesh, 1997, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.

An Unusual Presentation of Metastatic Squamous Cell Cervical Carcinoma Involving the Distal Ileum Mimicking Crohn’s Disease

K. Swenerton, E. Yoshida, K. Berean, 1994 .

Tea, coffee, and caffeinated beverage consumption and risk of epithelial ovarian cancers.

N. Le, M. Köbel, K. Swenerton, 2016, Cancer epidemiology.

Histotype predicts the curative potential of radiotherapy: the example of ovarian cancers.

N. Le, M. Köbel, K. Swenerton, 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

Differences in Tumor Type in Low-stage Versus High-stage Ovarian Carcinomas

D. Huntsman, M. Köbel, S. Kalloger, 2010, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.

Tumor type and substage predict survival in stage I and II ovarian carcinoma: insights and implications.

D. Huntsman, M. Köbel, S. Kalloger, 2010, Gynecologic oncology.

Kisspeptin and GPR54 immunoreactivity in a cohort of 518 patients defines favourable prognosis and clear cell subtype in ovarian carcinoma

D. Huntsman, S. McKinney, M. Köbel, 2007, BMC medicine.

The role of the fallopian tube in ovarian cancer.

A. Tinker, D. Huntsman, K. Swenerton, 2012, Clinical advances in hematology & oncology : H&O.

Adult height is associated with increased risk of ovarian cancer: a Mendelian randomisation study

Yurii B. Shvetsov, A. Whittemore, L. Kiemeney, 2018, British Journal of Cancer.

HER2 overexpression and amplification is present in a subset of ovarian mucinous carcinomas and can be targeted with trastuzumab therapy

Anna Adamiak, Russell Vang, C Blake Gilks, 2009, BMC Cancer.

European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion.

J B Vermorken, K. Swenerton, E. Eisenhauer, 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results.

M. Piccart, K. Swenerton, B. Zee, 2000, Journal of the National Cancer Institute.

Low-stage ovarian clear cell carcinoma: population-based outcomes in British Columbia, Canada, with evidence for a survival benefit as a result of irradiation.

A. Tinker, N. Le, K. Swenerton, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Better therapeutic trials in ovarian cancer.

E. Kohn, A. Oza, D. Huntsman, 2014, Journal of the National Cancer Institute.

A phase II study of the MDR inhibitor biricodar (INCEL, VX-710) and paclitaxel in women with advanced ovarian cancer refractory to paclitaxel therapy.

K. Swenerton, E. Ette, G. Batist, 2002, Gynecologic oncology.

Response to Maneo et al.

K. Swenerton, M. Plante, M. Roy, 2006 .

Preliminary evaluation of a multicenter, randomized comparative study of TAXOL (paclitaxel) dose and infusion length in platinum-treated ovarian cancer. Canadian-European Taxol Cooperative Trial Group.

E. Eisenhauer, K. Swenerton, W. W. ten Bokkel Huinink, 1993, Cancer treatment reviews.

A phase II study of sunitinib in patients with locally advanced or metastatic cervical carcinoma: NCIC CTG Trial IND.184.

A. Tinker, H. Mackay, E. Eisenhauer, 2010, Gynecologic oncology.

Prognostic factors in metastatic breast cancer treated with combination chemotherapy.

G. Hortobagyi, E. Gehan, K. Swenerton, 1979, Cancer research.

Amplification of 11q13 in ovarian carcinoma

C Blake Gilks, Joe Gray, David G Huntsman, 2008, Genes, chromosomes & cancer.

Evaluation of predictive formulae for glomerular filtration rate for carboplatin dosing in gynecological malignancies.

O. Djurdjev, A. Levin, K. Swenerton, 2006, Gynecologic oncology.

Flow cytometric assessment of DNA ploidy is a useful prognostic factor for patients with granulosa cell ovarian tumors

K. Swenerton, J. L. Le Riche, L. Elit, 1991, International Journal of Gynecologic Cancer.

Adult body mass index and risk of ovarian cancer by subtype: a Mendelian randomization study.

Yurii B. Shvetsov, A. Whittemore, L. Kiemeney, 2016, International journal of epidemiology.

Multivariate analysis of prognostic factors in metastatic breast cancer.

G. Hortobagyi, E. Gehan, K. Swenerton, 1983, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Complete remissions in metastatic breast cancer treated with combination drug therapy.

G. Hortobagyi, E. Gehan, K. Swenerton, 1979, Annals of internal medicine.

Exploring palliative treatment outcomes in women with advanced or recurrent ovarian clear cell carcinoma.

A. Tinker, K. Swenerton, C. Gilks, 2011, Gynecologic oncology.

A pilot phase 2 study of oregovomab murine monoclonal antibody to CA125 as an immunotherapeutic agent for recurrent ovarian cancer

K. Swenerton, Dianne Miller, T. Whiteside, 2004, International Journal of Gynecologic Cancer.

Significant hypersensitivity with paclitaxel managed by a 50 hour infusion

K. Swenerton, L. Nakashima, O. Keller, 1995 .

Adult lifetime alcohol consumption and invasive epithelial ovarian cancer risk in a population-based case-control study.

N. Le, K. Swenerton, A. Brooks-Wilson, 2016, Gynecologic oncology.

Combined oral contraceptive use before the first birth and epithelial ovarian cancer risk

N. Le, M. Köbel, K. Swenerton, 2016, British Journal of Cancer.

Impact of cyclophosphamide on relationships between carboplatin exposure and response or toxicity when used in the treatment of advanced ovarian cancer.

K. Swenerton, J. Burroughs, D. Jodrell, 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Oral etoposide is active against platinum-resistant epithelial ovarian cancer.

K. Swenerton, P. Hoskins, K. Swenerton, 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II study of carboplatin in patients with ovarian carcinoma: a National Cancer Institute of Canada Clinical Trials Group Study.

E. Eisenhauer, K. Swenerton, J. Sturgeon, 1986, Cancer treatment reports.

A phase II trial of intravenous etoposide (VP-16-213) in epithelial ovarian cancer resistant to cisplatin or carboplatin: clinical and serological evidence of activity

K. Swenerton, P. Hoskins, E. McMurtrie, 1991, International Journal of Gynecologic Cancer.

Small cell carcinoma of the cervix treated with concurrent radiotherapy, cisplatin, and etoposide.

K. Swenerton, P. Hoskins, E. McMurtrie, 1995, Gynecologic oncology.

Strategy for evaluation of a new antitumor agent in the treatment of breast cancer.

G. Hortobagyi, K. Swenerton, R. Benjamin, 1980, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

Occupational exposure and ovarian cancer risk

N. Le, K. Swenerton, A. Brooks-Wilson, 2014, Cancer Causes & Control.

Ten-year outcome of patients with advanced epithelial ovarian carcinoma treated with cisplatin-based multimodality therapy.

K. Swenerton, J. L. Benedet, P. Hoskins, 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

‘Moderate-risk’ ovarian cancer (stage I, grade 2; stage II, grade 1 or 2) treated with cisplatin chemotherapy (single agent or combination) and pelvi-abdominal irradiation

N. Le, K. Swenerton, P. Hoskins, 1993, International Journal of Gynecologic Cancer.

Platinum plus cyclophosphamide plus radiotherapy is superior to platinum alone in ‘high-risk’ epithelial ovarian cancer (residual negative and either stage I or II, grade 3, or stage III, any grade)

N. Le, K. Swenerton, P. Hoskins, 1994, International Journal of Gynecologic Cancer.

Randomized trial of two intravenous schedules of the topoisomerase I inhibitor liposomal lurtotecan in women with relapsed epithelial ovarian cancer: a trial of the national cancer institute of Canada clinical trials group.

Christopher Poole, Tien Le, Susan Ellard, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

High-dose-intensity regimen of weekly doxorubicin and cisplatin in the treatment of patients with stage III and IV epithelial ovarian carcinoma.

K. Swenerton, W. Shelley, G. Krepart, 1987, Cancer treatment reports.

Phase I clinical trial of recombinant human interleukin-3 combined with carboplatin in the treatment of patients with recurrent ovarian carcinoma.

E. Eisenhauer, K. Swenerton, N. Onetto, 1993, Journal of the National Cancer Institute.

Long‐term follow‐up confirms a survival advantage of the paclitaxel–cisplatin regimen over the cyclophosphamide–cisplatin combination in advanced ovarian cancer

M. Piccart, K. Swenerton, I. Vergote, 2003, International journal of gynecological cancer : official journal of the International Gynecological Cancer Society.

Long-term follow-up confirms a survival advantage of paclitaxel-cisplatin (CP) regimen over the cyclophosphamide-cisplatin (CP) combination in advanced ovarian cancer

M. Piccart, K. Swenerton, I. Vergote, 2002 .

Kisspeptin and GPR54 immunoreactivity in a cohort of 518 patients defines favourable prognosis and clear cell subtype in ovarian carcinoma.

D. Huntsman, S. McKinney, M. Köbel, 2007, BMC medicine.

"MECCA": a developmental, dose-intensive, non-cross-resistant platinum-based chemotherapy for advanced ovarian cancer.

K. Swenerton, P. Hoskins, E. McMurtrie, 1996, Gynecologic oncology.

A North American population-based outcome for early-stage ovarian clear cell carcinoma (OCCC).

A. Tinker, K. Swenerton, C. Gilks, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Kisspeptin and GPR54 immunoreactivity in a cohort of 518 patients defines favourable prognosis and clear cell subtype in ovarian carcinoma

D. Huntsman, S. McKinney, Erika Mehl, 2007, BMC medicine.

Response to hormonal therapy as a prognostic factor for metastatic breast cancer treated with combination chemotherapy

G. Hortobagyi, K. Swenerton, A. Buzdar, 1980, Cancer.